Resultados de la búsqueda 31-40 of 1306 for ���������������������������op������r���:za33���

  1. Hematología - Ensayos clínicos - Mayo Clinic

    ... (R/R) chronic lymphocytic leukemia (CLL). A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma. Rochester, Minn ...

  2. Anestesiología y medicina perioperatoria - Ensayos clínicos - Mayo Clinic

    The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...